Thieno-indole Alkylating Agents for Selective Cancer Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticancer alkylating agents often cause dose-limiting side effects due to their impact on rapidly proliferating normal cells, and they may have suboptimal physicochemical and pharmacokinetic properties, limiting their effectiveness and safety in treating tumors.
Innovation Solution
Development of novel alkylating agents comprising a thieno-indole moiety linked to a DNA-binding moiety, which are designed to improve targeting and pharmacokinetic properties, allowing for more selective cytotoxicity and reduced side effects by conjugating with various molecules to enhance tumor targeting and drug delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional alkylating agents are used to treat cancer, then cytotoxic activity against tumor cells is achieved, but dose-limiting side effects occur due to impact on rapidly proliferating normal cells
Solution Approach 1:
The alkylating agent is divided into two distinct functional components: a DNA-binding moiety (DBM) that provides sequence-specific targeting and an alkylating moiety (AM) that delivers the cytotoxic effect. This segmentation allows the DBM to guide the agent to cancer cell DNA while the AM remains activated only at the target site, reducing off-target effects on normal proliferating cells.
Solution Approach 2:
The patent creates local specificity by designing the DBM to recognize and bind to particular DNA sequences that are more abundant or accessible in cancer cells. This local quality enhancement ensures that the alkylating effect is concentrated at the tumor site rather than distributed systemically, thereby improving the therapeutic index.
2Quantity of substance
If conventional alkylating agents are used to achieve complete tumor eradication, then cytotoxic activity is maximized, but immunosuppression and gastrointestinal tract toxicity occur
Solution Approach 1:
The DNA-binding moiety acts as an intermediary that mediates between the alkylating agent and the target DNA in cancer cells. By introducing this intermediary component, the patent enables selective delivery of the cytotoxic alkylating group to tumor cells while sparing normal tissues, thus achieving complete tumor eradication without the severe systemic side effects of conventional agents.
3Quantity of substance
If conventional alkylating agents are administered at high doses to overcome resistance, then tumor cell killing is enhanced, but therapeutic window is reduced
Solution Approach 1:
The patent enhances local quality by designing the DNA-binding moiety to specifically recognize cancer cell DNA structures or sequences. This specificity ensures that even at lower doses, the alkylating agent is preferentially activated in tumor cells, maintaining an adequate therapeutic window while achieving effective tumor cell killing.
4Adaptability or versatility
If conventional alkylating agents are used, then broad spectrum anticancer activity is achieved, but physicochemical and pharmacokinetic properties are suboptimal
Solution Approach 1:
The patent applies universality by designing a modular architecture where the DNA-binding moiety can be coupled with different alkylating moieties to create variants with optimized physicochemical and pharmacokinetic properties. This multi-functionality allows maintenance of broad anticancer activity while enabling tailoring of solubility, stability, and metabolic characteristics for each specific agent.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a novel class of alkylating agents comprising a thieno-indole moiety linked to a DNA-binding moiety, which have cytotoxic activity and are useful in treating diseases such as cancer, cellular proliferation disorders and viral infections. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising them and methods of treating diseases utilizing such compounds or the pharmaceutical composition containing them. The invention also relates to the use of this novel class of alkylating agents in the preparation of conjugates.